Latest news

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award

Le professeur Peter Vogel nommé titulaire de la nouvelle chaire Debiopharm de philanthropie familiale à l’IMD

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…

GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market

Challenge Debiopharm-Inartis récompense les six finalistes 2017

Sonnedix acquires Aloe Energy with 67MW solar Portfolio in France

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor